



VIA REGISTERED POST AND EMAIL

Attention: Federico Gomez

President

Lab. Magnachem Intl. SRL

Bajos de Haina, Dominican Republic

Email: fgomez@magnachem.com; Jdia@Magnachem.com

Date: 5 June 2026

Re: Notice of Termination for the Nirmatrelvir Licence Agreement

Dear Mr. Gomez,

We refer to the licence agreement between the Medicines Patent Pool (“**MPP**”) and Lab. Magnachem Intl. SRL (“**Licensee**”) dated 3 July 2022 concerning patents and know-how pertaining to nirmatrelvir (“**Licence Agreement**”).

MPP is entitled to terminate this Licence Agreement with immediate effect pursuant to Section 12.3(c) of the Licence Agreement, as the Licensee failed to comply with its obligation under Section 3.7, specifically the requirement to submit a complete file for WHO Prequalification or any SRA approval within thirty-six (36) months from the Effective Date for any existing formulation of the Products (i.e. by 3 July 2025).

As such, please accept this letter as formal notice that, MPP hereby terminates the Licence Agreement with immediate effect.



This termination is without prejudice to the surviving provisions of the Licence Agreement, including those set out in Section 12.10.

Sincerely,

For and on behalf of Medicines Patent Pool

A handwritten signature in black ink, appearing to be 'CP', is positioned above a horizontal line.

Name: Chan Park

Title: General Counsel

Date: 5 June 2026